Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis

Laura J. Sherrard, Michael M. Tunney, J. Stuart Elborn*

*Corresponding author for this work

Research output: Contribution to journalLiterature review

61 Citations (Scopus)

Abstract

Cystic fibrosis is characterised by chronic polymicrobial infection and inflammation in the airways of patients. Antibiotic treatment regimens, targeting recognised pathogens, have substantially contributed to increased life expectancy of patients with this disease. Although the emergence of antimicrobial resistance and selection of highly antibiotic-resistant bacterial strains is of major concern, the clinical relevance in cystic fibrosis is yet to be defined. Resistance has been identified in recognised cystic fibrosis pathogens and in other bacteria (eg, Prevotella and Streptococcus spp) detected in the airway microbiota, but their role in the pathophysiology of infection and inflammation in chronic lung disease is unclear. Increased antibiotic resistance in cystic fibrosis might be attributed to a range of complex factors including horizontal gene transfer, hypoxia, and biofilm formation. Strategies to manage antimicrobial resistance consist of new antibiotics or localised delivery of antimicrobial agents, iron sequestration, inhibition of quorum-sensing, and resistome analysis. Determination of the contributions of every bacterial species to lung health or disease in cystic fibrosis might also have an important role in the management of antibiotic resistance. 

Original languageEnglish
Pages (from-to)703-713
Number of pages11
JournalThe Lancet
Volume384
Issue number9944
Early online date21 Aug 2014
DOIs
Publication statusPublished - 23 Aug 2014

Fingerprint

Microbiota
Cystic Fibrosis
Microbial Drug Resistance
Anti-Bacterial Agents
Prevotella
Inflammation
Horizontal Gene Transfer
Quorum Sensing
Biofilms
Anti-Infective Agents
Life Expectancy
Streptococcus
Coinfection
Lung Diseases
Chronic Disease
Iron
Bacteria
Lung
Health
Infection

Cite this

@article{5b569f18b7624455a3a5c50d4b9a82d5,
title = "Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis",
abstract = "Cystic fibrosis is characterised by chronic polymicrobial infection and inflammation in the airways of patients. Antibiotic treatment regimens, targeting recognised pathogens, have substantially contributed to increased life expectancy of patients with this disease. Although the emergence of antimicrobial resistance and selection of highly antibiotic-resistant bacterial strains is of major concern, the clinical relevance in cystic fibrosis is yet to be defined. Resistance has been identified in recognised cystic fibrosis pathogens and in other bacteria (eg, Prevotella and Streptococcus spp) detected in the airway microbiota, but their role in the pathophysiology of infection and inflammation in chronic lung disease is unclear. Increased antibiotic resistance in cystic fibrosis might be attributed to a range of complex factors including horizontal gene transfer, hypoxia, and biofilm formation. Strategies to manage antimicrobial resistance consist of new antibiotics or localised delivery of antimicrobial agents, iron sequestration, inhibition of quorum-sensing, and resistome analysis. Determination of the contributions of every bacterial species to lung health or disease in cystic fibrosis might also have an important role in the management of antibiotic resistance. ",
author = "Sherrard, {Laura J.} and Tunney, {Michael M.} and Elborn, {J. Stuart}",
year = "2014",
month = "8",
day = "23",
doi = "10.1016/S0140-6736(14)61137-5",
language = "English",
volume = "384",
pages = "703--713",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9944",

}

Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. / Sherrard, Laura J.; Tunney, Michael M.; Elborn, J. Stuart.

In: The Lancet, Vol. 384, No. 9944, 23.08.2014, p. 703-713.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis

AU - Sherrard, Laura J.

AU - Tunney, Michael M.

AU - Elborn, J. Stuart

PY - 2014/8/23

Y1 - 2014/8/23

N2 - Cystic fibrosis is characterised by chronic polymicrobial infection and inflammation in the airways of patients. Antibiotic treatment regimens, targeting recognised pathogens, have substantially contributed to increased life expectancy of patients with this disease. Although the emergence of antimicrobial resistance and selection of highly antibiotic-resistant bacterial strains is of major concern, the clinical relevance in cystic fibrosis is yet to be defined. Resistance has been identified in recognised cystic fibrosis pathogens and in other bacteria (eg, Prevotella and Streptococcus spp) detected in the airway microbiota, but their role in the pathophysiology of infection and inflammation in chronic lung disease is unclear. Increased antibiotic resistance in cystic fibrosis might be attributed to a range of complex factors including horizontal gene transfer, hypoxia, and biofilm formation. Strategies to manage antimicrobial resistance consist of new antibiotics or localised delivery of antimicrobial agents, iron sequestration, inhibition of quorum-sensing, and resistome analysis. Determination of the contributions of every bacterial species to lung health or disease in cystic fibrosis might also have an important role in the management of antibiotic resistance. 

AB - Cystic fibrosis is characterised by chronic polymicrobial infection and inflammation in the airways of patients. Antibiotic treatment regimens, targeting recognised pathogens, have substantially contributed to increased life expectancy of patients with this disease. Although the emergence of antimicrobial resistance and selection of highly antibiotic-resistant bacterial strains is of major concern, the clinical relevance in cystic fibrosis is yet to be defined. Resistance has been identified in recognised cystic fibrosis pathogens and in other bacteria (eg, Prevotella and Streptococcus spp) detected in the airway microbiota, but their role in the pathophysiology of infection and inflammation in chronic lung disease is unclear. Increased antibiotic resistance in cystic fibrosis might be attributed to a range of complex factors including horizontal gene transfer, hypoxia, and biofilm formation. Strategies to manage antimicrobial resistance consist of new antibiotics or localised delivery of antimicrobial agents, iron sequestration, inhibition of quorum-sensing, and resistome analysis. Determination of the contributions of every bacterial species to lung health or disease in cystic fibrosis might also have an important role in the management of antibiotic resistance. 

U2 - 10.1016/S0140-6736(14)61137-5

DO - 10.1016/S0140-6736(14)61137-5

M3 - Literature review

C2 - 25152272

AN - SCOPUS:84906658965

VL - 384

SP - 703

EP - 713

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9944

ER -